text Therapeutics (US:CNTX) Globenewswire·2025-11-05 21:15Core Insights - Context Therapeutics Inc. is advancing T cell engaging bispecific antibodies for solid tumors, with promising early clinical data for CTIM-76 and CT-95 [1][2][5][6] Pipeline Updates - CTIM-76: Currently in Phase 1 dose escalation for patients with ovarian, endometrial, or testicular cancer, showing preliminary signs of anti-tumor activity and a favorable safety profile [2][5] - CT-95: Also in Phase 1 dose escalation for various cancers, including pancreatic and non-small cell lung cancer, with expected target dose exposure starting at Cohort 4 [3][6] - CT-202: In preclinical development for multiple cancers, with plans for a first-in-human trial expected to begin in the second quarter of 2026 [4][7] Financial Results - As of September 30, 2025, cash and cash equivalents were $76.9 million, down from $94.4 million at the end of 2024, but expected to fund operations into 2027 [11][14] - Research and development expenses for Q3 2025 were $8.7 million, a decrease from $16.8 million in Q3 2024, primarily due to lower expenses related to CT-202 and CT-95 [11][13] - The net loss for Q3 2025 was $9.7 million, compared to a net loss of $17.5 million in Q3 2024, indicating improved financial performance [11][13]